Schlagloch-Ärger: So steht es um die Straßen im Landkreis | Freie Presse freiepresse.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freiepresse.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, Feb. 18, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn s disease and ulcerative colitis. Hoth executed an option agreement with Isoprene Pharmaceuticals, Inc. ( Isoprene ) to investigate the potential for the HT-003 API as an IBD therapeutic. Isoprene is a University of Maryland, Baltimore New Venture Initiative start-up company.
IBDs represent a large health burden in the United States, affecting approximately 3 million adults age 18 years and older that continues to increase each year.
Share this article
Share this article
NEW YORK, Jan. 20, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.
Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, is lead on the study. Thanks to Dr. Zippin and his team, we have gained significant insight for the therapeutic potential of HT-003 for the treatment of acne, stated Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics